JP2023553538A5 - - Google Patents

Info

Publication number
JP2023553538A5
JP2023553538A5 JP2023560246A JP2023560246A JP2023553538A5 JP 2023553538 A5 JP2023553538 A5 JP 2023553538A5 JP 2023560246 A JP2023560246 A JP 2023560246A JP 2023560246 A JP2023560246 A JP 2023560246A JP 2023553538 A5 JP2023553538 A5 JP 2023553538A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
composition according
arginine
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553538A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/063086 external-priority patent/WO2022132636A1/en
Publication of JP2023553538A publication Critical patent/JP2023553538A/ja
Publication of JP2023553538A5 publication Critical patent/JP2023553538A5/ja
Pending legal-status Critical Current

Links

JP2023560246A 2020-12-14 2021-12-13 抗csf1および抗csf1r抗体の高濃度製剤 Pending JP2023553538A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063125277P 2020-12-14 2020-12-14
US63/125,277 2020-12-14
US202163186684P 2021-05-10 2021-05-10
US63/186,684 2021-05-10
PCT/US2021/063086 WO2022132636A1 (en) 2020-12-14 2021-12-13 High concentration formulations of anti-csf1 and anti-csf1r antibodies

Publications (2)

Publication Number Publication Date
JP2023553538A JP2023553538A (ja) 2023-12-21
JP2023553538A5 true JP2023553538A5 (cg-RX-API-DMAC7.html) 2024-12-12

Family

ID=81942250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560246A Pending JP2023553538A (ja) 2020-12-14 2021-12-13 抗csf1および抗csf1r抗体の高濃度製剤

Country Status (4)

Country Link
US (3) US11419822B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065161A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553538A (cg-RX-API-DMAC7.html)
WO (1) WO2022132636A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553538A (ja) 2020-12-14 2023-12-21 エーマックス バイオ, インコーポレイテッド 抗csf1および抗csf1r抗体の高濃度製剤
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
EP4384277A4 (en) * 2021-08-12 2025-07-23 Ammax Bio Inc TARGETED DELIVERY OF ANTI-CSF1R ANTIBODIES
CN122404563A (zh) * 2026-06-18 2026-07-17 南京浦光生物科技有限公司 一种基于分子玻璃化外壳技术的抗体冻干球及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトc−fms抗原結合性タンパク質
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
EP3157957A1 (en) * 2014-06-23 2017-04-26 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US10040858B2 (en) * 2014-12-22 2018-08-07 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
AU2020283742A1 (en) * 2019-05-24 2021-09-16 Elixiron Immunotherapeutics (hong Kong) Limited Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof
JP2023553538A (ja) 2020-12-14 2023-12-21 エーマックス バイオ, インコーポレイテッド 抗csf1および抗csf1r抗体の高濃度製剤

Similar Documents

Publication Publication Date Title
JP7715635B2 (ja) イズロン酸2-スルファターゼを含むタンパク質分子の製剤
TWI459961B (zh) 長效人類生長激素共軛物之液態配方
ES2900624T3 (es) Formulación de anticuerpos
US7879805B2 (en) High temperature stable peptide formulation
CN103998060B (zh) 使用糖与多元醇的结合物稳定的依那西普制剂
JP7229999B2 (ja) ダプトマイシン製剤
EP3681483B1 (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
KR20130028894A (ko) 항체의 제제
US9125893B2 (en) Highly concentrated anti-CD40 antibody pharmaceutical preparation
JP2022105056A (ja) 高濃度の抗vegf抗体を含有するタンパク質溶液製剤
JP2019512012A5 (cg-RX-API-DMAC7.html)
JP2013525406A (ja) 安定mia/cd−rap製剤
JP2025087851A (ja) 安定な低粘度抗体製剤およびその使用
KR20220034053A (ko) 재조합 단백질의 안정적인 제형
EP3373953A1 (fr) Composition a action rapide d'insuline comprenant un citrate substitue
US11744902B2 (en) Targeting technology to selectively express mRNAs in cardiomyocytes while avoiding stimulation of cardiac fibroblasts
EP3207936B1 (en) Stable peptide composition
JPH1180021A (ja) バンコマイシン注射剤
TR2023017070T (tr) Pharmaceutical compositions of bevacizumab
HK40033832B (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
HK40033832A (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
EA043419B1 (ru) Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка